公司概覽
業務類別 Biotechnology
業務概覽 BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
公司地址 770 Lindaro Street, San Rafael, CA, USA, 94901
電話號碼 +1 415 506-6700
傳真號碼 +1 415 382-7889
公司網頁 https://www.biomarin.com
員工數量 3221
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Cristin Hubbard Executive Vice President and Chief Commercial Officer 美元 662.31K 21/04/2026
Ms. Rashmi Virendra Ramchandani Vice President and Chief Accounting Officer -- 21/04/2026
Mr. Alexander Hardy Director, President and Chief Executive Officer 美元 1.13M 21/04/2026
Mr. G. Eric Davis Executive Vice President, Chief Legal Officer and Secretary -- 21/04/2026
Mr. Brian R. Mueller Executive Vice President and Chief Financial Officer 美元 721.15K 21/04/2026
Dr. Charles Greg Guyer, PhD Chief Technical Officer and Executive Vice President 美元 697.12K 21/04/2026
Dr. Gregory R. Friberg, M.D. Executive Vice President and Chief Research and Development Officer 美元 705.65K 21/04/2026
 
董事會成員
董事會 職務 更新日期
Mr. Richard A. Meier Chairman of the Board 21/04/2026
Dr. Willard H. Dere, M.D. Independent Director 21/04/2026
Mr. Alexander Hardy Director, President and Chief Executive Officer 21/04/2026
Mr. Robert J. Hombach Independent Director 21/04/2026
Dr. Maykin Ho, PhD Independent Director 21/04/2026
Mr. Ian T. Clark Independent Director 21/04/2026
Ms. Elizabeth McKee Anderson, M.B.A. Independent Director 21/04/2026
Mr. Timothy P. Walbert Independent Director 21/04/2026
Ms. Barbara W. Bodem Independent Director 21/04/2026
Mr. Mark Joseph Enyedy Independent Director 21/04/2026
Dr. Athena Countouriotis, M.D. Independent Director 21/04/2026
 
所屬ETF (更新日期: 02/05/2026 04:43)
代號 名稱 佔比% 持有日期
DEUSXtrackers Russell US Multifactor ETF0.002%29/04/2026
MIDUDirexion Daily Mid Cap Bull 3X ETF0.002%28/04/2026
FHEQFidelity Hedged Equity ETF0.002%29/04/2026
TMFXMotley Fool Next ETF0.002%29/04/2026
CVLCCalvert US Large-Cp Cor Rspnb ETF0.002%29/04/2026
FNDBSchwab Fundamental U.S. Broad Market ETF0.001%29/04/2026
CTRUARK Transparency ETF0.001%30/06/2022
GDVGabelli Dividend & Income0.001%31/12/2025
BMEDiShares Health Innovation Active ETF0.001%28/04/2026
GVUSGoldman Sachs MktBt Russell LgCpValEqETF0.001%29/04/2026
AVSUAvantis Responsible US Equity ETF0.001%29/04/2026
SMDXIntech S&P Small-Mid Cap Divers Alp ETF0.001%29/04/2026
VLUState Street® SPDR® S&P® 1500 ValTiltETF0.001%29/04/2026
VSLUApplied Finance Valuation LgCp ETF0.001%29/04/2026
CVMCCalvert US Mid-Cp Cor Rspnb ETF0.001%29/04/2026
REVSColumbia Research Enhanced Value ETF0.001%04/02/2026
FYEEFidelity Yield Enhanced Equity ETF0.001%29/04/2026
DFLVDimensional US Large Cap Value ETF0.001%29/04/2026
UMDDProShares UltraPro MidCap4000.001%29/04/2026
ABCSAlpha Blue Capital US Sm-Md Cp Dyn ETF0.0005%29/04/2026
  1    2    3    4    5    6   7    8    9    10    11    12    13  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.